Drug profile · INN
valdecoxib
BEXTRA
valdecoxib (BEXTRA) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — valdecoxib
- US status
- approved
- Class
- Musculo-skeletal system (M01)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
valdecoxib (BEXTRA) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase-2 inhibitor
Primary target: Prostaglandin G/H synthase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is valdecoxib?
valdecoxib (BEXTRA) is a cyclooxygenase-2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for valdecoxib?
BEXTRA is a marketed brand name for valdecoxib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of valdecoxib?
valdecoxib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.